Dexcom (Nadsaq:DXCM) announced fourth-quarter results that came in mixed compared to the consensus forecast — but analysts are optimistic about 2025. Shares of DXCM initially fell after-hours yesterday on the after-market-close report — but by midday today, they were up more than 5% to $89.03 apiece. The San Diego-based continuous glucose monitor (CGM) maker reported […]
Wall Street Beat
Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus forecast. Shares of EMBC rose 1.65% to $18.50 apiece in pre-market trading today. The Parsippany, New Jersey-based diabetes technology company reported profits of $157.1 million. That equals $0 per share on sales of $261.9 million for the […]
Beta Bionics goes public with upsized $234.6M IPO
Beta Bionics (Nasdaq:BBNX) announced today that it went public after pricing a significantly upsized initial public offering (IPO). Earlier this month, the company filed a registration statement with the SEC relating to a proposed IPO. Beta Bionics, maker of the iLet bionic pancreas, later filed a prospectus outlining its aim to bring in $114.4 million in […]
Beta Bionics to raise $114.4M in IPO
Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO). Earlier this month, the maker of the iLet bionic pancreas filed a registration statement with the SEC relating to a proposed IPO. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market […]
Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024. The company’s medical device business saw a 13.7% overall increase in sales, with double-digit growth both in the U.S. and abroad. Abbott pointed to a number of products contributing to the performance, including the FreeStyle Libre continuous glucose monitor […]
Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
Dexcom expects sales to grow 14% in 2025
Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025. Shares of DXCM dipped 1.5% to $76.57 in mid-morning trading today. The San Diego-based continuous glucose monitor (CGM) maker reported preliminary 2024 revenues of $4.032 billion. That marks an 11% increase over 2023. For 2025, Dexcom anticipates total revenue of […]
Senseonics to consider reverse stock split, reports strong Eversense 365 interest
Senseonics (NYSE:SENS) announced preliminary financial results for 2024 as it considers a reverse stock split. Given a recent appreciation in the company’s share price, Senseonics decided not to proceed with a planned special meeting of stockholders. The company took this decision to consider the stock split. Shares of SENS rose 43% to 62¢ apiece at […]
Beta Bionics is proposing an IPO
Beta Bionics announced today that it filed a registration statement with the SEC relating to a proposed initial public offering (IPO). The amount of shares of common stock included in the IPO and the price range remain undetermined. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market under the “BBNX” […]
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as part of its fourth-quarter earnings results. The BD Diabetes spinoff won FDA approval for a disposable patch pump system […]
